Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018.,Nature Reviews Urology

当前位置： X-MOL 学术 › Nat. Rev. Urol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018.
Nature Reviews Urology ( IF 12.1 ) Pub Date : 2019-06-01 , DOI: 10.1038/s41585-019-0184-4
Yair Lotan ₁ , Trinity J Bivalacqua ₂ , Tracy Downs ₃ , William Huang ₄ , Jeffrey Jones ₅ , Ashish M Kamat ₆ , Badrinath Konety ₇ , Per-Uno Malmström ₈ , James McKiernan ₉ , Michael O'Donnell ₁₀ , Sanjay Patel ₁₁ , Kamal Pohar ₁₂ , Matthew Resnick ₁₃ , Alexander Sankin ₁₄ , Angela Smith ₁₅ , Gary Steinberg ₁₆ , Edouard Trabulsi ₁₇ , Michael Woods ₁₈ , Siamak Daneshmand ₁₉

Affiliation

UT Southwestern Medical Center, Dallas, TX, USA.
James Buchanan Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA.
Department of Urology, University of Wisconsin, Madison, WI, USA.
Department of Urology, New York University School of Medicine, New York, NY, USA.
Genitourinary Surgery Section, Michael E. DeBakey VA Medical Center, Houston, TX, USA.
Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Urology, University of Minnesota, Minneapolis, MN, USA.
Department of Urology, Institute of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Department of Urology, Columbia University Medical Center, New York City, NY, USA.
Department of Urology, University of Iowa, Iowa City, IA, USA.
Department of Urology, University of Oklahoma, Oklahoma City, OK, USA.
Department of Urology, Ohio State University, Columbus, OH, USA.
Department of Urologic Surgery, Vanderbilt University, Nashville, TX, USA.
Department of Urology, Montefiore Medical Center, New York, NY, USA.
Department of Urology, University of North Carolina, Chapel Hill, NC, USA.
Department of Urology, University of Chicago, Chicago, IL, USA.
Department of Urology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA.
Department of Urology, Loyola University Chicago, Chicago, IL, USA.
Department of Urology, University of Southern California, Los Angeles, CA, USA.

Blue light cystoscopy (BLC) with hexaminolevulinate (HAL) during transurethral resection of bladder cancer improves detection of non-muscle-invasive bladder cancer (NMIBC) and reduces recurrence rates. Flexible BLC was approved by the FDA in 2018 for use in the surveillance setting and was demonstrated to improve detection. Results of a phase III prospective multicentre study of blue light flexible cystoscopy (BLFC) in surveillance of intermediate-risk and high-risk NMIBC showed that 20.6% of malignancies were identified only by BLFC. Improved detection rates in the surveillance setting are anticipated to lead to improved clinical outcomes by reducing future recurrences and earlier identification of tumours that are unresponsive to therapy. Thus, BLFC has a role in surveillance cystoscopy, and determining which patients will benefit from BLFC and optimal and cost-effective ways of incorporating this technology into surveillance cystoscopy must be developed.

中文翻译：

蓝光灵活膀胱镜检查在非肌肉浸润性膀胱癌中使用六氨基乙酰丙酸酯：在美国最佳使用的临床证据和共识声明的综述-2018年更新。

膀胱癌经尿道切除术中的蓝光膀胱镜检查（BLC）和六氨基乙酰丙酸盐（HAL）改善了非肌肉浸润性膀胱癌（NMIBC）的检测率，并降低了复发率。灵活的BLC于2018年被FDA批准用于监视环境，并被证明可以提高检测效率。蓝光柔性膀胱镜（BLFC）监测中危和高危NMIBC的III期前瞻性多中心研究结果表明，只有BLFC可以识别出20.6％的恶性肿瘤。通过减少将来的复发和对治疗无反应的肿瘤的早期识别，预期在监视环境中提高的检出率将导致改善的临床结果。因此，BLFC在监视性膀胱镜检查中具有一定的作用，

更新日期：2019-05-16

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>